文献速递乳腺癌

卡培他滨作为新辅助/辅助化疗组成部分的效应:一项纳入13项随机试验15993例乳腺癌患者个体数据的Meta分析

Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients.
PubMed 文献 · Eur J Cancer · 2022-03-16

该Meta分析汇集13项随机试验中15993例早期乳腺癌患者个体数据,评估卡培他滨加入新辅助/辅助化疗对无病生存(DFS)和总生存(OS)的影响。总体 adding 卡培他滨未显著改变DFS(HR 0.952;95%CI 0.895-1.012;P=0.115),但在标准治疗基础上加用卡培他滨可改善DFS(HR 0.888;95%CI 0.817-0.965;P=0.005)和OS(HR 0.837;95%CI 0.751-0.933;P=0.001),三阴性乳腺癌(TNBC)患者获益。

要点

  • 总体加用卡培他滨未显著改善DFS(HR 0.952;95%CI 0.895-1.012;P=0.115)。
  • 在标准系统治疗基础上加用卡培他滨改善DFS(HR 0.888;95%CI 0.817-0.965;P=0.005)和OS(HR 0.837;95%CI 0.751-0.933;P=0.001)。
  • TNBC患者从卡培他滨治疗中获益,包括DFS和OS。

核心结论

  • 在TNBC患者中以及所有早期乳腺癌患者中,当卡培他滨加用于系统治疗时,可改善DFS和OS。

研究设计与样本

  • 检索ClinicalTrials.gov和PubMed,纳入早期乳腺癌辅助或新辅助治疗中使用卡培他滨的多中心随机试验(>100例患者),共13项试验、15993例患者个体数据。

主要发现

  • 全部患者中加用卡培他滨对比不加卡培他滨,DFS无显著差异(HR 0.952;95%CI 0.895-1.012;P=0.115)。
  • 在卡培他滨替代其他药物的研究中,DFS无显著差异(HR 1.035;95%CI 0.945-1.134;P=0.455)。
  • 在标准系统治疗基础上加用卡培他滨,DFS改善(HR 0.888;95%CI 0.817-0.965;P=0.005)。
  • 全部队列中观察到OS改善(HR 0.892;95%CI 0.824-0.965;P=0.005),加用卡培他滨亚组中OS改善(HR 0.837;95%CI 0.751-0.933;P=0.001)。
  • 亚组分析显示TNBC患者从卡培他滨治疗中总体获益,在加用于其他系统治疗时DFS和OS均获益。

关键数值与推荐

  • DFS:全部患者HR 0.952(95%CI 0.895-1.012;P=0.115);替代其他药物亚组HR 1.035(95%CI 0.945-1.134;P=0.455);加用亚组HR 0.888(95%CI 0.817-0.965;P=0.005)。
  • OS:全部队列HR 0.892(95%CI 0.824-0.965;P=0.005);加用亚组HR 0.837(95%CI 0.751-0.933;P=0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite the large number of patients with early breast cancer (EBC) who have been treated with capecitabine in randomised trials, no individual patient data meta-analysis has been conducted. The primary objective was to examine the effect of capecitabine on disease-free survival (DFS), and the secondary objectives were to analyse distant DFS (DDFS), overall survival (OS), pathological complete response (for neoadjuvant studies) and the interaction between capecitabine-related toxicity and treatment effect. METHODS: www. CLINICALTRIALS: gov and www.pubmed.ncbi.nlm.nih.gov were searched using the following criteria: use of capecitabine for EBC as adjuvant or neoadjuvant therapy; multicentre randomised trial with >100 patients; recruitment completed, and outcomes available. Required data were available for 13 trials. RESULTS: Individual data from 15,993 patients were collected. Cox regression analyses of all included patients revealed that the addition of capecitabine did not alter DFS significantly compared with treatment without capecitabine (hazard ratio [HR] 0.952; 95% CI 0.895-1.012; P value = 0.115). There was also no effect on DFS in the subset of studies where capecitabine was given instead of another drug (HR 1.035; 95% CI 0.945-1.134; P = 0.455). However, capecitabine administered in addition to the standard systemic treatment improved DFS (HR 0.888; 95% CI 0.817-0.965; P = 0.005). An OS improvement was observed in the entire cohort (HR 0.892; 95% CI 0.824-0.965, P = 0.005) and in the subset of capecitabine addition (HR 0.837; 95% CI 0.751, 0.933, P = 0.001). Subgroup analyses revealed that triple-negative breast cancer (TNBC) patients benefitted from treatment with capecitabine overall and in addition to other systemic treatments in terms of DFS and OS. CONCLUSION: Capecitabine was able to improve DFS and OS in patients with TNBC and in all patients with EBC when administered in addition to systemic treatment.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. van Mackelenbergh MT, Seither F, Möbus V, et al. Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients. Eur J Cancer. 2022. PMID: 35305453. doi:10.1016/j.ejca.2022.02.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。